7808.Two
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with a current ratio of 19.7, indicating a high ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of -97,426,000 TWD and a negative return on equity of -8.02%. These figures suggest that the company is not generating returns for shareholders at this time.
The company's profitability is below the industry median, as evidenced by the negative operating income of -116,446,000 TWD and a negative return on assets of -7.59%. These metrics indicate that the company is not effectively utilizing its assets to generate profit, which is a concern for investors.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess the geographic or segment concentration of its revenue. This lack of detail limits the ability to evaluate the company's exposure to specific markets or products.
The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or historical growth rates. The negative operating cash flow of -57,484,000 TWD and the negative free cash flow of -168,849,000 TWD suggest that the company is not generating sufficient cash from operations to fund its activities.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is supported by a low debt-to-equity ratio of 0.01, indicating that it is primarily financed through equity.
The company has not disclosed any recent events, such as filings or transcripts, that would provide insight into its current operations or strategic direction. This lack of recent activity may indicate a period of stability or a lack of significant developments.
- The company has a strong liquidity position, as indicated by a high current ratio of 19.7.
- The company is currently unprofitable, with a net loss of -97,426,000 TWD and a negative return on equity of -8.02%.
- The company's profitability is below the industry median, with a negative operating income of -116,446,000 TWD and a negative return on assets of -7.59%.
- The company's growth trajectory is uncertain, as the available data does not provide forward-looking revenue projections or historical growth rates.
- margin_outlook_rationale: The company's margin outlook is negative due to the current net loss and negative return on equity.
- rd_outlook_rationale: The company's R&D outlook is uncertain as there is no specific information provided on R&D expenditures or future R&D plans.
- capex_outlook_rationale: The company's capital expenditure outlook is negative, as indicated by the negative capital expenditure of -83,188,000 TWD.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7808.TWO Market data — financials · 2026-05-27